Please assess the completion status of the following clinical trial:

Trial Title: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants chronically infected with HCV Genotype 4~* HCV RNA viral load of ≥ 10,000 IU/mL~* No previous exposure to an interferon formulation, RBV or HCV direct antiviral agent~* Results of a liver biopsy obtained within three years prior to enrollment to demonstrate the absence of cirrhosis. Participants with compensated cirrhosis are permitted, however, and any prior biopsy is permitted~Exclusion Criteria:~* Evidence of decompensated liver disease~* Documented or suspected Hepatocellular carcinoma (HCC)~* Positive for Hepatitis B surface antigen (HBsAg) or Human immunodeficiency virus-1 (HIV-1)/HIV-2 antibody at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-790052 + PegIFNα-2a + Ribavirin (Type: EXPERIMENTAL): * BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~* PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~* Ribavirin 400 mg (2 tablets for participants \< 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response
- Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin (Type: PLACEBO_COMPARATOR): * Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~* PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~* Ribavirin 400 mg (2 tablets for participants \< 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).